{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:17:41Z","timestamp":1788250661080,"version":"build-2803163510"},"reference-count":20,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Background: Studies have confirmed that the progression of sepsis is closely related to intestinal barrier dysfunction, including intestinal mucosa ischemia and hypoxia, flora imbalance and epithelial cell apoptosis. Therefore, protecting the intestinal barrier function has become a key link in the comprehensive treatment of sepsis. Objectives: This study evaluated the impact of a novel ?-lactamase inhibitor compound preparation (ceftazidime\/avibactam) on intestinal barrier function in sepsis patients. Methods: The study included 108 sepsis patients (January 2022?August 2025) and grouped them as an observation group (54 cases, ceftazidime\/avibactam+dynamic nutritional support) and a control group (54 cases, Ceftazidime\/Sulbactam+dynamic nutritional support). Of the outcome measures assessed, the 28-day all-cause mortality was primary, while ICU length of stay, mechanical ventilation time, antibiotic course, intestinal barrier function markers (DAO, LBP, Claudin-1) and inflammatory cytokines (IL-6, TNF-?) were secondary. Results: The results indicated lower 28-day all-cause mortality in the observation group vs the control group, along with shorter ICU length of stay, mechanical ventilation time and time to negative blood culture conversion (P&lt;0.05). Concerning post-treatment intestinal barrier function, DAO, LBP and FC were lower while claudin-1 was higher in the observation group compared to the control group (P&lt;0.05). Analysis of inflammatory factors also showed greater reductions in IL-1?, IL-6 and TNF-? in the observation group post-treatment (P&lt;0.05). Conclusion: Ceftazidime\/Avibactam plus dynamic nutritional support is instrumental in improving the intestinal barrier function of sepsis patients and alleviating inflammatory reactions, thus enhancing life safety.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.6.153.1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:15:21Z","timestamp":1775304921000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact Of Ceftazidime\/Avibactam Combined Dynamic Nutritional Support On Intestinal Barrier Function In Sepsis Patients: A Focus On Barrier Protection Mechanisms"],"prefix":"10.36721","author":[{"given":"Xiaojuan","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Almangour TA, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, Almohaizeie A, Almuhisen S, Alghaith J, Damfu N, Aljefri D, Alfahad W, Khormi Y, Alanazi MQ and Alsowaida YS (2023). Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant pseudomonas aeruginosa: A multicenter cohort study. Antimicrob Agents Chemother, 67(8): e0040523.","DOI":"10.1128\/aac.00405-23"},{"key":"ref1","unstructured":"Bo S, Zhao Z, Xi J and Yao G (2023). Effect of enteral nutritional support on clinical outcomes of patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 35(1): 71-76."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Castanheira M, Doyle TB, Hubler CM, Collingsworth TD, DeVries S and Mendes RE (2022). The plethora of resistance mechanisms in Pseudomonas aeruginosa: Transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel beta-lactam\/beta-lactamase inhibitor combinations. J Glob Antimicrob Resist, 31: 72-79.","DOI":"10.1016\/j.jgar.2022.07.021"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cha JK, Kim HS, Kim EJ, Lee ES, Lee JH and Song IA (2022). Effect of early nutritional support on clinical outcomes of critically Ill patients with sepsis and septic shock: A single-center retrospective study. Nutrients, 14(11): 2318","DOI":"10.3390\/nu14112318"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Chen CM, Tang HL, Chiou CS, Tung KC, Lu MC and Lai YC (2021). Colonization dynamics of Klebsiella pneumoniae in the pet animals and human owners in a single household. Vet Microbiol, 256: 109050.","DOI":"10.1016\/j.vetmic.2021.109050"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Gupta N, Boodman C, Prayag P, Manesh A and Kumar TP (2024). Ceftazidime-avibactam and aztreonam combination for carbapenem-resistant enterobacterales bloodstream infections with presumed metallo-beta-lactamase production: A systematic review and meta-analysis. Expert Rev Anti Infect Ther., 22(4): 203-209.","DOI":"10.1080\/14787210.2024.2307912"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hsu W, Chuang MH, Tsai WW, Lai CC, Lai HY and Tang HJ (2024). Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: A systemic review and meta-analysis. Infection, 52(5): 2029-2042.","DOI":"10.1007\/s15010-024-02277-y"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, Li L, Cao J, Xu F, Zhou Y, Guan CX, Jin SW, Deng J, Fang XM, Jiang JX and Zeng L (2022). Sepsis-induced immunosuppression: Mechanisms, diagnosis and current treatment options. Mil Med Res, 9(1): 56.","DOI":"10.1186\/s40779-022-00422-y"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Martin-Loeches I, Singer M and Leone M (2024). Sepsis: Key insights, future directions and immediate goals. A review and expert opinion. Intensive Care Med., 50(12): 2043-2049.","DOI":"10.1007\/s00134-024-07694-z"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Matesanz M and Mensa J (2021). Ceftazidime-avibactam. Rev Esp Quimioter, 34(Suppl1): 38-40.","DOI":"10.37201\/req\/s01.11.2021"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mekadim C, Mrazek J, Fliegerova KO, Sechovcova H, Mahayri TM, Jarosikova R, Husakova J, Woskova V, Tuma P, Polak J, Sojakova D, Nemcova A, Dubsky M and Fejfarova V (2025). The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers - DFIATIM trial. BMC Microbiol, 25(1): 339.","DOI":"10.1186\/s12866-025-04041-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Naveed M, Mughal MS, Jabeen K, Aziz T, Naz S, Nazir N, Shahzad M, Alharbi M, Alshammari A and Sadhu SS (2022). Evaluation of the whole proteome to design a novel mRNA-based vaccine against multidrug-resistant Serratia marcescens. Front Microbiol, 13: 960285.","DOI":"10.3389\/fmicb.2022.960285"},{"key":"ref12","unstructured":"Ohta T, Makino I, Okazaki M, Miyashita T and Tajima H (2021). Intestinal care using L\u2012glutamine supplement and probiotics can induce a strong anti\u2012tumor immune response through the induction of mature tertiary lymphoid structures in pancreatic cancer patients receiving preoperative chemotherapy. Gan To Kagaku Ryoho, 48(4):465-471."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Srzic I, Nesek Adam V and Tunjic Pejak D (2022). Sepsis definition: What's new in the treatment guidelines. Acta Clin Croat, 61(Suppl 1): 67-72.","DOI":"10.20471\/acc.2022.61.s1.11"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, Luzzati R, Grossi PA, Corona A, Capone A, Falcone M, Mussini C, Trecarichi EM, Cascio A, Guffanti E, Russo A, De Pascale G, Tascini C, Gentile I, Losito AR, Bussini L, Corti G, Ceccarelli G, Corcione S, Compagno M, Giacobbe DR, Saracino A, Fantoni M, Antinori S, Peghin M, Bonfanti P, Oliva A, De Gasperi A, Tiseo G, Rovelli C, Meschiari M, Shbaklo N, Spanu T, Cauda R and Viale P (2021). Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study. Clin Infect Dis, 73(9): 1664-1676.","DOI":"10.1093\/cid\/ciab176"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Watson RS, Carrol ED, Carter MJ, Kissoon N, Ranjit S and Schlapbach LJ (2024). The burden and contemporary epidemiology of sepsis in children. Lancet Child Adolesc Health, 8(9): 670-681.","DOI":"10.1016\/S2352-4642(24)00140-8"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wetzel C, Lonneman M and Wu C (2021). Polypharmacological drug actions of recently FDA approved antibiotics. Eur J Med Chem., 209: 112931.","DOI":"10.1016\/j.ejmech.2020.112931"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, Zhu Y, Xu Y and Yang Q (2024). Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae. Microbiology spectrum, 12(6): e0010724.","DOI":"10.1128\/spectrum.00107-24"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Yan Z, Niu L, Wang S, Gao C and Pan S (2024). Intestinal Piezo1 aggravates intestinal barrier dysfunction during sepsis by mediating Ca(2+) influx. J Transl Med., 22(1): 332.","DOI":"10.1186\/s12967-024-05076-z"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zhang X, Liu H, Hashimoto K, Yuan S and Zhang J (2022). The gut-liver axis in sepsis: Interaction mechanisms and therapeutic potential. Critical care (London, England), 26(1): 213.","DOI":"10.1186\/s13054-022-04090-1"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:54:37Z","timestamp":1788249277000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.6.153.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}